A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting. - Jones S; Falchook G; Graff S; Arrowsmith E; Kilari D; Gersten TA; Hussein M; Percent I; Burris HA 3rd (The oncologist, 2026)